ARWR · NASDAQ · STOCK
Arrowhead Pharmaceuticals (ARWR) Stock Analysis
$62.78
52W $34.61 – $95.49
53/100
$8.84B
-28.0
1.30
Is ARWR Bullish or Bearish?
Mixed.
Innellis AI committee rates Arrowhead Pharmaceuticals (ARWR) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.40 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.60 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Value Analyst remains cautious — price-to-book of 10.0x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 10.0x prices in significant intangible value — Value
- ROE of only -60.5% -- cheap may mean cheap for a reason — Value
- Weekly RSI at 25 -- oversold on the larger timeframe too — Technical
- Bollinger bandwidth of 26.9% signals elevated volatility — Risk
- News sentiment is negative (-0.25 across 4 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 82%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 10.0x prices in significant intangible value
Growth Analyst
bullish
75
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
− Weekly RSI at 25 -- oversold on the larger timeframe too
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 26.9% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
49
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.25 across 4 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 50.1 to 52.6.
- Committee agreement increased notably from 33% to 50%.
- New bearish signals: 2 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 4 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: stance neutral->bullish; score 46->61 (+15); +1 bearish signal(s); +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
36.1
Neutral
MACD Histogram
0.040
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Mixed
Support
$60.67
Resistance
$69.51
Bollinger %B
0.30
Inside Bands
Price vs Moving Averages
EMA 9
$63.34
Below
EMA 21
$67.63
Below
EMA 50
$73.73
Below
EMA 200
$69.16
Below
Fundamental Analysis
Valuation
67
Growth
52
Profitability
25
Financial Health
66
Cash Flow
15
Valuation
P/E Ratio
-28.0×
P/B Ratio
19.33×
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$95.49
52W Low
$34.61
Quality & Growth
ROE
-35.0%
ROA
-11.8%
Gross Margin
10000.0%
Operating Margin
-3382.2%
Revenue Growth YoY
—
Debt / Equity
1.86
AI Fundamental Assessment
P/E ratio of -28.0 (inexpensive relative to a 15-40x range); Price-to-book of 19.3x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -0.3%; Return on assets of -0.1%; Net margin of -47.8%; Gross margin of 100.0%; Current ratio of 5.90 (healthy short-term liquidity); Debt-to-equity of 1.86; Free cash flow per share is negative (-0.52); Most recent quarter missed estimates by 1.0%; EPS growth accelerating (-522.7% -> -46.2% QoQ); Average YoY EPS growth of -7.9%; Analyst estimates falling over recent quarters
Get the Full ARWR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →